Aiforia
Paid, subscription-based
Regulatory Status Disclosed
Overview
Aiforia offers AI-powered solutions for medical image analysis, primarily in pathology. The platform is designed for pathologists and scientists in clinical, preclinical, and academic laboratory settings.
- What it does: Aiforia’s AI tools analyze large and complex medical images, aiming to enhance the speed, accuracy, and consistency of analysis. Their offerings include pre-developed AI models for specific pathologies, such as breast, lung, prostate, gastric, and colorectal cancers. Additionally, Aiforia® Create is an AI development tool that allows users to build deep learning AI models for image analysis in digital pathology, even without prior AI experience.
- Who it is for: The solutions are intended for pathologists and researchers across various specialties involved in diagnostic pathology and medical research. Care settings include clinical pathology laboratories, research institutions, and academic medical centers.
- How it fits a clinical or practice workflow: Aiforia’s clinical solutions provide automated, case-centric workflows for pathology labs, aiming to integrate with existing laboratory infrastructure. The AI applications are designed to assist in diagnostic workflows by providing tools for comprehensive analysis and reporting. For research, the platform offers automated study-centric workflows and image analysis applications to streamline repetitive tasks.
- Notable capabilities: Key capabilities include a portfolio of AI solutions for various cancer types, a cloud-based collaborative environment for AI model development with Aiforia® Create, and fully automated workflows for both clinical and research applications.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Deep learning AI for image analysis in digital pathology
- Cloud-based, collaborative working environment
- Fully automated study-centric workflows for research
- AI solutions portfolio for clinical and preclinical applications (e.g., Breast Cancer Suite, Lung Cancer Suite, Prostate Cancer Suite, Gastric Suite)
- Aiforiau00ae Create for developing custom AI models without coding
- Integration with existing laboratory infrastructure (LIS, LIMS, PACS, IMS, scanners)
- Automated quantification and report preparation
- Support for various 2D image formats, including brightfield and fluorescence
- Multi-level encryption and secure data storage
- CE-IVD marked AI models for diagnostic use in EU and EEA countries
Use Cases
- Enhancing speed, accuracy, and consistency of analyzing large and complex medical images in pathology
- Automating breast cancer grading and assessment of IHC markers
- Detecting and quantifying PD-L1 in non-small cell lung cancer cases
- Supporting detection of gastric cancer and Helicobacter pylori
- Developing custom AI models for various image analysis applications in research and clinical settings
- Automating repetitive tasks in research within GLP framework
What Physicians Need to Know
Whole Slide Image Support
Aiforia's platform is designed to analyze whole slide images (WSI) from various high-resolution scanners, including Aperio ScanScope AT Turbo. It supports major image file formats like TIFF and SVS.
Digital Pathology Integration
Aiforia's solutions are built for seamless integration into existing digital pathology systems, including LIS, LIMS, PACS, IMS, and scanners, to enable automated workflows. They partner with companies like Techcyte (Fusion Digital Pathology Platform), Dedalus (InVitro Anatomic Pathology Information System), Proscia (Concentriqu00ae platform), and Aurora mScope for integrated AI-driven workflows.
Stain Compatibility
The platform is compatible with any type of biological sample or staining. Specifically, Aiforia's AI models are used with H&E-stained FFPE gastric tissue, H&E-stained whole-slide images for breast cancer grading, and reticulin stain for mesothelioma subtyping. They also offer solutions for IHC quality control.
Biomarker Detection Capabilities
Aiforia's AI models assist in biomarker detection and quantification. Examples include quantification of ER, PR, and HER2 in breast cancer, Ki67 in breast and other cancer types (thyroid, neuroendocrine, pancreas, lung), and PD-L1 in non-small cell lung cancer.
Turnaround Time Impact
Aiforia's AI-assisted workflows can significantly reduce diagnostic processing time, with reported reductions of up to 68% in some pathology applications through automated quantification and report preparation. Studies have shown a 34% reduction in time for Gleason pattern analysis per slide with AI assistance.
CAP/CLIA Compliance
While not explicitly stating CAP/CLIA compliance, Aiforia emphasizes its adherence to globally relevant quality and security certifications, including ISO 13485 (Quality Management System), ISO 27001 (Information Security Management System), and SOC 2 Type II security standards. They also comply with GDPR and HIPAA regulations. Their clinical AI models are CE-IVD marked for diagnostic use in EU and EEA countries.
Supported Cancer Types
Aiforia offers clinical suites for Breast Cancer, Lung Cancer, Prostate Cancer, Colon Cancer, and Gastric Cancer. Specific AI models support detection and quantification in breast cancer (grading, ER, PR, HER2, Ki67, lymph node metastasis), colorectal cancer (lymph node metastasis, QuantCRC for recurrence prediction), gastric cancer (detection of gastric cancer and H. pylori), lung cancer (PD-L1), and prostate cancer (Gleason grade grouping, perineural invasion, Gleason Grade 4 Cribriform, high-grade PIN).
Quantitative Analysis Features
Aiforia provides fully quantifiable data and results, assisting pathologists in tasks such as cell counting, tumor measurements, tumor grading, and biomarker detection and quantification. Their platform supports object detection, semantic segmentation (for area quantification), and instance segmentation (for quantifying merging or overlapping areas individually). They also offer automated mitotic counting and spatial analysis.
LIS Integration
Aiforia has a specialized integration team to ensure seamless integration of the Aiforiau00ae Platform into existing laboratory information systems (LIS), as well as LIMS, PACS, and IMS. They have established partnerships for integration with Dedalus' InVitro Anatomic Pathology Information System, Techcyte's Fusion Digital Pathology Platform, and Aurora mScope Clinical.
Physician Tip
Aiforia's AI models serve as first-read support, providing quantifiable data and results that can be easily adjusted in an interactive user interface, allowing pathologists to rapidly review areas of interest and complete case reviews. The platform aims to increase diagnostic precision and speed, shorten turnaround times, and improve patient outcomes. The ability to build and validate custom AI models with Aiforiau00ae Create, even without prior AI experience, offers significant flexibility for specialized diagnostic needs and research. The system's transparency, offering visual, pixel-level analysis and quantitative data, allows pathologists to maintain full control and verify AI results.
Aiforia prioritizes seamless integration with existing laboratory infrastructure, including various digital pathology systems and LIS/LIMS. Their open and inclusive web-based API enables broad integration with commercial or custom applications. Strategic partnerships with major digital pathology platform providers like Techcyte, Dedalus, Proscia, and Aurora mScope ensure that AI-driven insights can be seamlessly incorporated into routine workflows, removing technical barriers to AI adoption. This focus on integration helps streamline diagnostic work and reporting, making AI an indispensable everyday tool without disrupting existing processes.
Details
| Category | Pathology AI |
| Pricing |
Paid, subscription-based
|
| Deployment | Cloud-based |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Pending AI-estimated Aiforia is working towards securing its first regulatory approval in the United States, with an application to the FDA anticipated in 2024. |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Pathology, Radiology |
What the Web Says
Aiforia offers AI-powered, cloud-based solutions for image analysis in pathology, aiming to enhance the speed, accuracy, and consistency of diagnoses in both preclinical and clinical laboratories. Their platform helps pathologists and researchers with tasks like identifying disease biomarkers, accelerating drug development, and improving cancer diagnostic accuracy. Aiforia's Clinical Suites provide AI-driven diagnostic tools, intelligent visualization, and automated pre- and post-screening functionalities, with CE-IVD certification for their AI solutions in lung and breast cancer.
Overall: PositiveStrengths
- Increases diagnostic accuracy and consistency.
- Boosts productivity and efficiency in pathology labs by automating time-consuming tasks.
- Reduces inter-pathologist variability in scoring and analysis.
- Facilitates faster time to diagnosis, improving patient outcomes.
- Cloud-based platform allows for collaborative work and accessibility without dedicated hardware.
- User-friendly interface, allowing pathologists without data science or coding expertise to develop AI models.
Limitations
- No specific cons were found in the provided search results from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra.
- Some alternative AI platforms for pathology may have more extensive features or different pricing models.
Based on reviews from: Slashdot, FeaturedCustomers, SourceForge, Aiforia (aiforia.com), Dealroom.co, YouTube
Last updated: 2026-10-03
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Aiforia
Press & Coverage
Aiforia Technologies Plc
Aiforia and Stratipath partner to expand access to AI-driven precision diagnostics in oncology
Aiforia and Stratipath announced a strategic partnership to provide broader access to AI-powered diagnostic and prognostic tools for pathologists and oncologists. This collaboration aims to enhance AI-driven diagnostics in pathology.
2026-08
Aiforia Technologies Plc
Aiforia announces the next generation of its CE-IVD marked Prostate Cancer Biopsy AI solution
Aiforia launched the next generation of its CE-IVD marked clinical AI solution for prostate cancer diagnostics, designed to enhance pathologists' workflow for comprehensive analysis and reporting of prostate needle biopsies.
2026-03
Aiforia Technologies Plc
Aiforia releases a new CE-IVD marked AI solution for gastric cancer diagnostics
Aiforia announced the launch of a new CE-IVD marked clinical AI solution for gastric cancer diagnostics, which supports pathologists in the detection and reporting of gastric cancer in digitized tissue samples.
2026-02
Aiforia Technologies Plc
Aiforia and the European Investment Bank have signed an agreement for EUR 20 million venture debt financing
The European Investment Bank (EIB) is providing u20ac20 million in venture debt financing to Aiforia to further develop its AI-powered platform for digital tissue analysis, particularly for tumor detection. This funding, supported by the InvestEU program, will accelerate product development and commercial operations.
2026-07
Dealroom News
Aiforia Technologies raises ~u20ac6.4M in directed share issue | Dealroom News
Finnish medtech firm Aiforia Technologies raised approximately u20ac6.4 million through a directed share issue to institutional and qualified investors to fund its growth strategy. The company issued 3,600,000 new shares at u20ac1.772 each.
2026-06
Aiforia Technologies Plc
Aiforia secures IVDR certification, paving the way for expanded clinical portfolio in Europe
Aiforia successfully obtained IVDR certification and launched three new CE-IVD marked AI solutions for breast and prostate cancer diagnostics, confirming compliance with stringent safety and performance requirements.
2025-02
Aiforia Technologies Plc
Aiforia initiates path to secure its first regulatory approval in the United States u2013 application to the FDA anticipated in 2024
Aiforia Technologies Plc is pursuing regulatory approval for its first product in the United States, with an application to the FDA anticipated in 2024 to meet the increasing demand for digital pathology image analysis in clinical diagnostics.
2023-10
Aiforia
Case study: AI-assisted prostate cancer diagnosis
A study demonstrated that AI-assisted support, using Aiforia Prostate Cancer Suite, can reduce inter-observer variability among pathologists and serve as a second opinion or triage tool for prostate cancer diagnosis. The AI model showed high concordance with visual diagnosis.
2024-07
Videos
Product demos, reviews, and walkthroughs for Aiforia.
Customer story: Aiforia's solutions at AP-HP
Aiforia
Frequently Asked Questions
Aiforia's AI can assist with various pathology tasks, including quantification of biomarkers, tumor detection, and classification of tissue types. It integrates into your workflow by providing AI-powered analysis of whole-slide images, which can be viewed and interpreted within Aiforia's platform or integrated with existing LIS/PACS systems.
Aiforia ensures accuracy through rigorous validation processes, including extensive training on diverse datasets and independent clinical studies. Their algorithms are developed under a quality management system compliant with medical device regulations, and performance data is often published in peer-reviewed journals.
Aiforia's platform and AI models are developed with regulatory compliance in mind. Many of their solutions carry CE-IVD marking for in vitro diagnostic use in Europe, and they are actively pursuing FDA clearance for relevant applications in the United States.
Aiforia typically offers flexible pricing models that can include per-case fees, subscription-based access, or custom enterprise solutions. They aim to accommodate various practice sizes and research institutions, with options tailored to specific usage volumes and feature requirements.
While highly accurate, Aiforia's AI, like all AI, has limitations, such as potential performance variations with rare or unusual tissue presentations. Safeguards include requiring pathologist oversight and final interpretation, clear labeling of AI-generated results, and continuous monitoring and updates to the algorithms.
Aiforia prioritizes data privacy and security through robust encryption, access controls, and adherence to relevant regulations like GDPR and HIPAA. Their platform is designed with secure data handling protocols to protect sensitive patient information throughout the analysis process.
Aiforia provides comprehensive support and training, including onboarding programs, user manuals, and technical assistance. They offer resources to help pathologists and lab staff integrate the AI solutions seamlessly into their workflow and maximize their benefits.
Suggest an Edit →
| Last Verified: 2026-07-01 | First Added: 2026-07-01